Lactobacillus johnsonii La1 attenuates Helicobacter pylori-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 12, 2005, Pages 1378-1386

  Sgouras, Dionyssios N ^a   Panayotopoulou, Effrosini G ^a   Martinez Gonzalez, Beatriz ^a   Petraki, Kalliopi ^a   Michopoulos, Spyros ^b   Mentis, Andreas ^a  

^a HELLENIC PASTEUR INSTITUTE   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; CYTOKINE; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 8; KERATINOCYTE DERIVED CYTOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; PROTEIN LA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATTENUATION; BACTERIAL COLONIZATION; CELL PH; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EARLY DIAGNOSIS; GASTRITIS; HELICOBACTER PYLORI; IMMUNOMODULATION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS AMYLOVORUS; LACTOBACILLUS JOHNSONII; LACTOBACILLUS JOHNSONII LA1; LAMINA PROPRIA; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, BACTERIAL; COLONY COUNT, MICROBIAL; FOLLOW-UP STUDIES; GASTRIC MUCOSA; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOGLOBULIN G; INTERLEUKIN-8; LACTOBACILLUS; LYMPHOCYTES; MICE; MICE, INBRED C57BL; NEUTROPHIL INFILTRATION;

EID: 29144469007     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.12.1378-1386.2005     Document Type: Article

References (55)

1. Aiba, Y., N. Suzuki, A. M. Kabir, A. Takagi, and Y. Koga. 1998. Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic marine model. Am. J. Gastroenterol. 93:2097-2101.
2. Armstrong, D. A., J. A. Major, A. Chudyk, and T. A. Hamilton. 2004. Neutrophil chemoattractant genes KC and MIP-2 are expressed in different cell populations at sites of surgical injury. J. Leukoc. Biol. 75:641-648.
3. Avonts, L., and L. De-Vuyst. 2001. Antimicrobial potential of probiotic lactic acid bacteria. Meded. Fac. Landbouwkd. Toegep. Biol. Wet. Univ. Gent 66:543-545.
4. Bergey, B., P. Marchildon, J. Peacock, and F. Megraud. 2003. What is the role of serology in assessing Helicobacter pylori eradication? Aliment. Pharmacol. Ther. 18:635-639.
5. Bernet-Camard, M.-F., V. Liévin, D. Brassart, J.-R. Neeser, A. L. Servin, and S. Hudault. 1997. The human Lactobacillus acidophilus strain LA1 secretes a nonbacteriocin antibacterial substanee(s) active in vitro and in vivo. Appl. Environ. Microbiol. 63:2747-2753.
6. Bozic, C. R., L. F. Kolakowski, Jr., N. P. Gerard, C. Garcia-Rodriguez, C. von Uexkull-Guldenband, M. J. Conklyn, R. Breslow, H. J. Showell, and C. Gerard. 1995. Expression and biologic characterization of the murine chemokine KC. J. Immunol. 154:6048-6057.
7. Callewaert, R., H. Holo, B. Devreese, J. Van Beeumen, I. Nes, and L. De Vuyst. 1999. Characterization and production of amylovorin L471, a bacteriocin purified from Lactobacillus amylovorus DCE 471 by a novel three-step method. Microbiology 145:2559-2568.
8. Canducci, F., A. Armuzzi, F. Cremonini, G. Cammarota, F. Bartolozzi, P. Pola, G. Gasbarrini, and A. Gasbarrini. 2000. A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates. Aliment. Pharmacol. Ther. 14:1625-1629.
9. Cats, A., E. J. Kuipers, M. A. R. Bosschaert, R. G. J. Pot, C. M. J. E. Vandenbroucke-Grauls, and J. G. Kusters. 2003. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment. Pharmacol. Ther. 17:429-435.
10. Chamaillard, M., M. Hashimoto, Y. Horie, J. Masumoto, S. Qiu, L. Saab, Y. Ogura, A. Kawasaki, K. Fukase, S. Kusumoto, M. A. Valvano, S. J. Foster, T. W. Mak, G. Nunez, and N. Inohara. 2003. An essential role for NOD1 in host recognition of bacterial peptidoglycan containing diaminopimelic acid. Nat. Immunol. 4:702-707.
11. Coconnier, M.-H., V. Lievin, E. Hemery, and A. L. Servin. 1998. Antagonistic activity against Helicobacter infection in vitro and in vivo by the human Lactobacillus acidophilus strain LB. Appl. Environ. Microbiol. 64:4573-4580.
12. Crabtree, J. E., J. I. Wyatt, L. K. Trejdosiewicz, P. Peichl, P. H. Nichols, N. Ramsay, J. N. Primrose, and I. J. Lindley. 1994. Interleukin-8 expression in Helicobacter pylori infected, normal, and neoplastic gastroduodenal mucosa. J. Clin. Pathol. 47:61-66.
13. Cremonini, F., S. Di Caro, M. Covino, A. Armuzzi, M. Gabrielli, L. Santarelli, E. C. Nista, G. Cammarota, G. Gasbarrini, and A. Gasbarrini. 2002. Effect of different probiotic preparations on anti-Helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am. J. Gastroenterol. 97:2744-2749.
14. Cruchet, S., M. C. Obregon, G. Salazar, E. Diaz, and M. Gotteland. 2003. Effect of the ingestion of a dietary product containing Lactobacillus johnsonii La1 on Helicobactcr pylori colonization in children. Nutrition 19:716-721.
15. De Francesco, V., V. Stoppino, C. Sgarro, and D. Faleo. 2000. Lactobacillus acidophilus administration added to omeprazole/amoxycillin-based double therapy in Helicobacter pylori eradication. Dig. Liver Dis. 32:746-747.
16. Dixon, M. F., R. M. Genta, J. H. Yardley, P. Correa, et al. 1996. Classification and grading of gastritis. The updated Sydney system. Am. J. Surg. Pathol. 20:1161-1181.
17. Driscoll, K. E. 1994. Macrophage inflammatory proteins: biology and role in pulmonary inflammation. Exp. Lung Res. 20:473-490.
18. Eck, M., B. Schmausser, K. Scheller, A. Toksoy, M. Kraus, T. Menzel, H. K. Müller-Hermelink, and R. Gillitzer. 2000. CXC chemokines Groα/IL-8 and IP-10/MIG in Helicobacter pylon gastritis. Clin. Exp. Immunol. 122:192-199.
19. Endlich, B., D. Armstrong, J. Brodsky, M. Novotny, and T. A. Hamilton. 2002. Distinct temporal patterns of macrophage-inflammatory protein-2 and KC chemokine gene expression in surgical injury. J. Immunol. 168:3586-3594.
20. Fanti, L., R. Ieri, G. Mezzi, P. A. Testoni, S. Passaretti, and M. Guslandi. 2001. Long-term follow-up and serologic assessment after triple therapy with omeprazolc or lansoprazole of Helicobacter-associated duodenal ulcer. J. Clin. Gastroenterol. 32:45-48.
21. Felley, C. P., I. Corthesy-Theulaz, J. L. Rivero, P. Sipponen, M. Kaufmann, P. Bauerfeind, P. H. Wiesel, D. Brassart, A. Pfeifer, A. L. Blum, and P. Michetti. 2001. Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man. Eur. J. Gastroenterol. Hepatol. 13:25-29.
22. Ferrero, R. L., J. M. Thiberge, M. Huerre, and A. Labigne. 1998. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection. Infect. Immun. 66:1349-1355.
23. Frémaux, C., C. Ahn, and T. R. Klaenhammer. 1993. Molecular analysis of the lactacin F operon. Appl. Environ. Microbiol. 59:3906-3915.
24. Garhart, C. A., R. W. Redline, J. G. Nedrud, and S. J. Czinn. 2002. Clearance of Helicobacter pylori infection and resolution of postimmunization gastritis in a kinetic study of prophylactically immunized mice. Infect. Immun. 70: 3529-3538.
25. Genta, R. M., G. M. Lew, and D. Y. Graham. 1993. Changes in the gastric mucosa following eradication of Helicobacter pylori. Mod. Pathol. 6:281-289.
26. Gotteland, M., and S. Cruchet. 2003. Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers. J. Antimicrob. Chemother. 51:1317-1319.
27. Hamilton-Miller, J. M. 2003. The role of probiotics in the treatment and prevention of Helicobacter pylori infection. Int. J. Antimicrob. Agents 22: 360-366.
28. Heinrich, J. N., and R. Bravo. 1995. The orphan mouse receptor interleukin (IL)-8R beta binds N51. Structure-function analysis using N51/IL-8 chimeric molecules. J. Biol. Chem. 270:4987-4989.
29. Inohara, N., Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, S. J. Foster, A. P. Moran, J. L. Fernandez-Luna, and G. Nunez. 2003. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J. Biol. Chem. 278:5509-5512.
30. Johnson-Henry, K. C., D. J. Mitchell, Y. Avitzur, E. Galindo-Mata, N. L. Jones, and P. M. Sherman. 2004. Probiotics reduce bacterial colonization and gastric inflammation in H. pylori-infected mice. Dig. Dis. Sci. 49:1095-1102.
31. Kabir, A. M., Y. Aiba, A. Takagi, S. Kamiya, T. Miwa, and Y. Koga. 1997. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model. Gut 41:49-55.
32. Kim, D. H., S. W. Kim, Y. J. Song, T. Y. Oh, S. U. Han, Y. B. Kim, H. J. Joo, Y. K. Cho, D. Y. Kim, S. W. Cho, M. W. Kim, J. H. Kim, and K. B. Hahm. 2003. Long-term evaluation of mice model infected with Helicobacter pylori: focus on gastric pathology including gastric cancer. Aliment. Pharmacol. Ther. 18:14-23.
33. Lee, A., J. O'Rourke, M. C. De Ungria, B. Robertson, G. Daskalopoulos, and M. F. Dixon. 1997. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112:1386-1397.
34. Mähler, M., C. Janke, S. Wagner, and H. J. Hedridi. 2002. Differential susceptibility of inbred mouse strains to Helicobacter pylori infection. Scand. J. Gastroenterol. 37:267-278.
35. Malfertheiner, P., F. Mégraud, C. O'Morain, A. P. S. Hungin, K. Jones, A. Axon, D. Y. Graham, G. Tytgat, and The European Helicobacter Pylori Study Group (EHPSG). 2002. Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment. Pharmacol. Ther. 16:167-180.
36. Martin, R. M., J. L. Brady, and A. M. Lew. 1998. The need for IgG2c specific antiserum when isotyping antibodies from C57BLr6 and NOD mice. J. Immunol. Methods 212:187-192.
37. Michetti, P., G. Dorta, P. H. Wiesel, D. Brassart, E. Verdu, M. Herranz, C. Felley, N. Porta, M. Rouvet, A. L. Blum, and I. Corthésy-Theulaz. 1999. Effect of whey-based culture supernatant of Lactobacillus acidophilus (johnsonii) La1 on Helicobacter pylori infection in humans. Digestion 60:203-209.
38. Obonyo, M., D. G. Guiney, J. Harwood, J. Fierer, and S. P. Cole. 2002. Role of gamma interferon in Helicobacter pylori induction of inflammatory mediators during murine infection. Infect. Immun. 70:3295-3299.
39. Obonyo, M., D. G. Guiney, J. Fierer, and S. P. Cole. 2003. Interactions between inducible nitric oxide and other inflammatory mediators during Helicobacter pylori infection. Helicobacter 8:495-502.
40. Pantoflickova, D., I. Corthesy-Theulaz, G. Dorta, M. Stolte, P. Isler, F. Rochat, M. Enslen, and A. L. Blum. 2003. Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis. Aliment. Pharmacol. Ther. 18:805-813.
41. Peña, J. A., A. B. Rogers, Z. Ge, V. Ng, S. Y. Li, J. G. Fox, and J. Versalovic. 2005. Probiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice. Infect. Immun. 73:912-920.
42. Schall, T. J. 1994. The chemokines, p. 419-460. In A. Thomson (ed.), The cytokine handbook, 2nd ed. Academic Press, Inc., San Diego, Calif.
43. Servin, A. L. 2004. Antagonistic activities of lactobacilli and bifidobacteria against microbial pathogens. FEMS Microbiol. Rev. 28:405-440.
44. Sgouras, D., P. Maragkoudakis, K. Petraki, B. Martinez-Gonzalez, E. Eriotou, S. Michopoulos, G. Kalantzopoulos, E. Tsakalidou, and A. Mentis. 2004. In vitro and in vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl. Environ. Microbiol. 70:518-526.
45. Sharma, S. A., M. K. R. Tummuru, M. J. Blaser, and L. D. Kerr. 1998. Activation of IL-8 gene expression by Helicobacter pylori is regulated by transcription factor nuclear factor-κB in gastric epithelial cells. J. Immunol. 160:2401-2407.
46. Siegmund, B., H. A. Lehr, G. Fantuzzi, and C. A. Dinarello. 2001 IL-1 beta-converting enzyme (caspase-1) in intestinal inflammation. Proc. Natl. Acad. Sci. USA 98:13249-13254.
47. Stolte, M., and S. Eidt. 1992. Chronic erosions of the antral mucosa: a sequela of Helicobacter pylori-induced gastritis. Z. Gastroenterol. 30:846-850.
48. Sutton, P., J. Wilson, and A. Lee. 2000. Further development of the Helicobacter pylori mouse vaccination model. Vaccine 18:2677-2685.
49. Takahashi, M., H. Taguchi, H. Yamaguchi, T. Osaki, and S. Kamiya. 2000. Studies of the effect of Clostridium butyricum on Helicobacter pylori in several test models including gnotobiotic mice. J. Med. Microbiol. 49:635-642.
50. Ushiyama, A., K. Tanaka, Y. Aiba, T. Shiba, A. Takagi, T. Mine, and Y. Koga. 2003. Lactobacillus gasseri OLL2716 as a prohiotic in clarithromycin- resistant Helicobacter pylori infection. J. Gastroenterol. Hepatol. 18:986-991.
51. Viala, J., C. Chaput, I. G. Boneca, A. Cardona, S. E. Girardin, A. P. Moran, R. Athman, S. Memet, M. R. Huerre, A. J. Coyle, P. S. DiStefano, P. J. Sansonetti, A. Labigne, J. Bertin, D. J. Philpott, and R. L. Ferrero. 2004. Nod1 responds to peptidoglycan delivered hy the Helicobacter pylori cag pathogenicity island. Nat. Immunol. 5:1166-1174.
52. Vidal, K., A. Donnet-Hughes, and D. Granato. 2002. Lipoteichoic acids from Lactobacillns johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria. Infect. Immun. 70:2057-2064.
53. Watanabe, T., A. Kitani, P. J. Murray, and W. Strober. 2004. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat. Immunol. 5:800-808.
54. Yamaoka, Y., M. Kita, T. Kodama, N. Sawai, T. Tanahashi, K. Kashima, and J. Imanishi. 1998. Chemokines in the gastric mucosa in Helicobacter pylori infection. Gut 42:609-617.
55. Zamfir, M., R. Callewaert, P. C. Cornea, L. Savu, I. Vatafu, and L. De Vuyst. 1999. Purification and characterization of a bacteriocin produced by Lactobacillus acidophilus 1BB 801. J. Appl. Microbiol. 87:923-931.